Immunoglobulin News and Research

RSS

Researchers test commercial assays to detect SARS-CoV-2 antibodies six months after infection

Researchers at the Hospices Civils de Lyon (HCL) in France found that people infected with SARS-CoV-2 can develop antibodies that persist for up to six months. After testing commercial assays to detect antibodies, the Wantai antibody assay has a positivity rate of 100%.

14 Dec 2020

Case study suggests kindergartens are not SARS-CoV-2 super-spreaders

A new study by researchers at the Institute of Tropical Medicine and International Health at the Charite Universitaetsmedizin Berlin found that kindergartens are not silent transmission reservoirs.

11 Dec 2020

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

A recent study by US researchers, currently available on the medRxiv preprint server, evaluated several cell-based assays that are under validation for determining correlates of protection in individuals with symptomatic coronavirus disease (COVID-19) and vaccine studies – and demonstrated their high concordance with both live and pseudotyped virions.

9 Dec 2020

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

A new study published on the preprint server bioRxiv in December 2020 indicates the ability of anti-SARS-CoV-2 antibody titers and time of induction to differentiate between severe and mild COVID-19 and could lead to the development of a prognostic biomarker for use early in the course of the illness.

8 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Designed proteins assemble antibodies into modular nanocages

With cues from nature, designing functional molecules enables scientists to nanoengineer and customize for specific uses.

3 Dec 2020

Novel “multitope” vaccine shows promise in the fight against COVID-19

Researchers have demonstrated the potential of a protein-peptide vaccine to protect against infection with SARS-CoV-2, the agent that causes COVID-19.

3 Dec 2020

A new potential COVID-19 vaccine candidate: YF-S0

A recent study published in the journal Nature describes the safety and efficacy of a live-attenuated yellow fever 17D (YF17D) vector-based vaccine candidate expressing a non-cleavable form of the spike protein of severe acute respiratory coronavirus 2 (SARS-CoV2).

2 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Memory B cells persist in recovered COVID-19 patients

A team of scientists from the University of Washington, USA, and the Karolinska Institute, Sweden, has comprehensively studied the antibody-mediated immune responses in patients diagnosed with coronavirus disease 2019 (COVID-19).

30 Nov 2020

Researchers highlight potential advantages of mucosal vaccine

Anyone who has undergone a nasal swab or saliva test for COVID-19 knows that the virus is most easily detected in the nose and mouth.

30 Nov 2020

COVID-19 studies have neglected to focus on mucosal immunity, researchers argue

Researchers suggest that COVID-19 studies should focus on how mucous membranes in the mouth and nose develop immunity to the SARS-CoV-2 virus.

27 Nov 2020

SARS-CoV-2 immunity can sustain for at least eight months, study finds

A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.

26 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

In a recent study published in the preprint server bioRxiv, researchers from the Grifols Bioscience Research Group reported on the collection of convalescent plasma and production of anti-SARS-CoV-2 hyperimmune globulin for use in clinical research.

22 Nov 2020

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased. They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

19 Nov 2020

Study: e-cigarette users have increased susceptibility to flu, COVID-19

In a controlled study of smokers, nonsmokers, and e-cigarette users, University of North Carolina School of Medicine researchers found that e-cigarette users exhibited significantly altered immune responses to a model of influenza virus infection, suggesting increased susceptibility to disease.

18 Nov 2020

SARS-CoV-2 was circulating in Italy before China recognized its existence

This study, published in the Tumori Journal, sheds light on the possibility that the virus had been spreading in Italy well before the outbreak was officially reported in Wuhan, China.

17 Nov 2020